Early-stage preclinical chemistry and pharmacology study demonstrating lead compound design and in vivo efficacy in xenograft models, without clinical trial data or regulatory approval.
Early-stage in vitro mechanistic work demonstrating a novel compound design principle and cellular effects in cancer cells, without clinical trial data or in vivo efficacy validation.
This is a proof-of-concept chemical synthesis and mechanism study demonstrating a novel drug design strategy in cells and xenografts, lacking clinical endpoints or comparison to standard therapy.